<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34937">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651740</url>
  </required_header>
  <id_info>
    <org_study_id>SXZ-WSD01-2015</org_study_id>
    <nct_id>NCT02651740</nct_id>
  </id_info>
  <brief_title>Gut Microbiota Reconstruction for the Treatment of Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
  <official_title>Gut Microbiota Reconstruction for the Treatment of Diarrhea-predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy as well as safety of rifaximin and
      fecal microbiota transplantation in the treatment of IBS-D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For IBS-D patients, rifaximin and fecal microbiota transplantation are given separately or
      together in order to evaluate the efficacy and safety of these two therapies compared with
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with relief of IBS core symptoms ( abdominal pain and stool consistency )</measure>
    <time_frame>4 weeks after the treatment</time_frame>
    <description>The proportion of patients who have relief of abdominal pain (daily assessed according to 0-10 point scoring system, with 0 indicating no pain at all and 10 indicating very great deal of pain, patients record the most severe pain in a day) and stool consistency (according to Bristol type) during the 4 weeks after the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with relief of other specific IBS symptoms besides abdominal pain and stool consistency ( including global IBS symptoms, stool frequency and IBS-related bloating )</measure>
    <time_frame>4 weeks after the treatment</time_frame>
    <description>The proportion of patients who have relief of global IBS symptoms、 stool frequency、IBS-related bloating during the 4 weeks after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with relief of any IBS-related syptoms( including global IBS symptoms, abdominal pain, bloating, stool consistency and frequency )</measure>
    <time_frame>12 weeks after the treatment</time_frame>
    <description>The proportion of patients who have relief of global IBS symptoms、abdominal pain/bloating/stool consistency/stool frequency during the 12 weeks after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with improvement of quality of life</measure>
    <time_frame>4/12/24 weeks after the treatment</time_frame>
    <description>The improvement of quality of life is measured by SF36-V2 and EQ-5D</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The rate and type of adverse effects</measure>
    <time_frame>The last day of the treatment and 4/8/12/24 weeks after the treatment</time_frame>
    <description>It means any events that occur in the trial process related or unrelated to the drug/FMT that do harm to the patients' health, including symptoms/physical signs/abnormal lab values</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>taking placebo and then infusing saline through enteral nutrition tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking rifaximin and then infusing saline through enteral nutrition tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking placebo and then FMT with donor stool through enteral nutrition tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking rifaximin and then FMT with donor stool through enteral nutrition tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>200mg tid* 3d</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <other_name>vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>200mg tid* 3d</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_label>Combined</arm_group_label>
    <other_name>Brand name: XIFAXAN; Production company: SALIX PHARMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>infusing saline through enteral nutrition tube</intervention_name>
    <description>250ml per time for at least once</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FMT with donor stool through enteral nutrition tube</intervention_name>
    <description>250ml per time for at least once</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_label>Combined</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 65, no gender limitation;

          -  Had received a diagnosis of IBS-D (as assessed according to the Rome III diagnosis
             criteria of IBS) and had undergone a colonoscopic examination within the previous 2
             years with no organic lesions observed;

          -  Has current symptoms of IBS-D: ①Abdominal pain (rated the average daily amount of
             abdominal pain as a score of more than 3 on a 0-10 point scoring system in a week
             (with 0 indicating no pain at all and 10 for a very great deal of pain)); ② Stool
             consistency (rated the consistency of their stools of Bristol types 6/7 (loose or
             watery) at least once a day and at least 2 days in a week);

          -  Can do follow-up at required time points and signed written informed consent before
             the study.

        Exclusion Criteria:

          -  Allergic to rifaximin;

          -  Taking alosetron, tegaserod, lubiprostone, warfarin, or antipsychotic, antispasmodic,
             antidiarrheal, probiotic, or narcotic drugs within the previous 1 month;

          -  Had infective diarrhea history or had taken antibiotics within the previous 14 days;

          -  Patients with a history of inflammatory bowel disease ;

          -  Previous abdominal surgery (other than cholecystectomy or appendectomy);

          -  Human immunodeficiency virus infection or other immunodeficiency conditions such as
             congenital immunodeficiency or currently taking immune-suppression drugs;

          -  Unstable diabetes, hypertension, thyroid disease, etc;

          -  Accompanied malignant tumor or severe heart/lung/renal/hepatic/brain/blood diseases;

          -  Accompanied severe neural/psychotic diseases such as epilepsy, depression, mania,
             schizophrenia, etc;

          -  Other conditions that doctor thought not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xizhong Shen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Zhongshan Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengdi Wu</last_name>
    <phone>(86)13817923359</phone>
    <email>wu.shengdi@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengdi Wu</last_name>
      <phone>(86)13817923359</phone>
      <email>wu.shengdi@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 8, 2016</lastchanged_date>
  <firstreceived_date>January 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifaximin</keyword>
  <keyword>Fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
